A Life Sciences Fortuitous Opportunity: NASA's Twins Study
This article was originally published in Scrip
Executive Summary
While the goal of the yearlong mission aboard the International Space Station (ISS) involving US astronaut Scott Kelly and his Russian counterpart cosmonaut Mikhail Kornienko, who both returned to Earth on March 2, was intended to examine the effects of microgravity on the human body with the aim of reducing the health risks on future crewmembers, NASA serendipitously fell into a fortuitous situation to study spaceflight at the molecular level, potentially providing the life sciences sector a wealth of data – an opportunity that may not come around again for quite some time, if at all.
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.